Navigation Links
Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
Date:2/5/2009

Repligen Corporation. "Our financial resources will allow us to continue to advance our clinical programs and aggressively pursue the acquisition of new product candidates for our pipeline in 2009."

For the nine-month period ended December 31, 2008, total revenue was $24,768,000 compared to $15,996,000 for the same period in fiscal year 2008. Operating expenses for the nine-month period were $17,672,000, compared to $16,409,000, exclusive of the net gain of $40,170,000 from a litigation settlement, for the same period in fiscal year 2008. Net income for the nine-month period was $8,439,000 or $0.27 per diluted share compared to net income of $40,304,000 or $1.29 per diluted share in the same period in fiscal year 2008.

Corporate Update

RG1068 for Imaging of the Pancreas

We are currently enrolling patients in a Phase 3 clinical trial of RG1068, synthetic human secretin, designed to assess the ability of RG1068 enhanced magnetic resonance imaging (MRI) to improve the detection of pancreatic duct abnormalities compared to MRI alone. Detailed visual assessment of the pancreatic ducts is important in the diagnosis and treatment of diseases such as acute and chronic pancreatitis. This study is being conducted at approximately 25 clinical sites within the U.S. and Canada and will enroll approximately 250 patients. The FDA has granted this program Fast Track Designation, a process designed to facilitate the development and expedite the review of drugs that treat serious diseases and fill an unmet medical need. There are more than 300,000 procedures conducted in the U.S. and Europe each year that may benefit from enhancement with RG1068.

RG2417 for Bipolar Disorder

We are currently enrolling a Phase 2b clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar depression. This is a multi-center, randomized, double-blind, placebo-controlled
'/>"/>

SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
2. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
3. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
4. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
5. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
6. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
7. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
8. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
9. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
10. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
11. Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , September 1, 2015 Shire plc ... Sara Mathew to its Board of Directors as ... the Audit, Compliance & Risk Committee of the Shire Board. ... Sara previously served as Chairman, President and Chief ... December 2013. During her 12-year tenure at D&B, she helped ...
(Date:8/31/2015)... DIEGO , Aug. 31, 2015 MabVax ... development company announces that the Company,s lead antibody, HuMab ... of five separate presentations during the upcoming World Molecular ... September 2-5, 2015. Researchers from the Department ... will present results on the use of MabVax,s lead ...
(Date:8/31/2015)... , Aug. 31, 2015 Research and ... the "Middle East & Africa Biomedical Sensors Market ... their offering. The Middle ... estimated at $0.84 billion by 2018 at a CAGR ... near future will bring Biomedical sensors that are adaptable ...
(Date:8/31/2015)... SYDNEY , Aug. 31, 2015  US-Australian ... NVGN ) today confirmed its comprehensive scientific ... ground-breaking technology platforms in areas of unmet patient ... through the remaining preclinical projects prior to entering ... lead compounds. Acting Chief Executive Officer, ...
Breaking Biology Technology:Shire Appoints Sara Mathew to Board of Directors 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 3MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 4Middle East & Africa Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts to 2020 2Novogen Announces The Outcome Of A Comprehensive Science Review 2Novogen Announces The Outcome Of A Comprehensive Science Review 3Novogen Announces The Outcome Of A Comprehensive Science Review 4Novogen Announces The Outcome Of A Comprehensive Science Review 5Novogen Announces The Outcome Of A Comprehensive Science Review 6
... Mulcahy Madison, Wis. The University of ... of its leaders in the field of stem-cell research. R. ... graduate biological studies, will be leaving UW-Madison to become vice ... , ,Tim will be missed, graduate school Dean Martin Cadwallader ...
... Doyle announced today on the University of Wisconsin campus a ... fields of biotechnology, health sciences, and stem cell research. The ... the state over the next several years, and he outlined ... Discovery on the UW-Madison campus. , ...
... the help of Wisconsin-based ABC Computers , Jack ... with the requirements of big distributors such as Wal-Mart, which ... their products. , ,Jack Links is headquartered in Minong, Wisconsin. ... Microsofts Navision program and several other partners to ...
Cached Biology Technology:UW-Madison associate dean, active in stem cells, leaves 2Wisconsins governor unveils $750 million investment for stem cell and health research 2North-woods beef jerky maker adopts RFID to track shipments 2North-woods beef jerky maker adopts RFID to track shipments 3
(Date:8/20/2015)... Calif. , Aug. 20, 2015 ... on consumers that are active and healthy. However, ... in the hospital environment to help improve diagnostic ... a video from the Wearable Technologies Conference ... discussed new applications for wearables in healthcare.    ...
(Date:8/19/2015)... , Aug. 19, 2015  VOXX International Corporation ... has entered into a Definitive Agreement to purchase ... iris authentication market leader EyeLock through an acquiring ... have a controlling interest in the acquiring entity. ... completion of due diligence.  Expanding on its existing ...
(Date:8/17/2015)... , Aug. 17, 2015  NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market and ... sales campaign for Q4 2015. The new marketing campaign ... consisting of Amplitude Marketing Group ( http://amplitudemarketing.com/ ) and ... is a leader in retail driven marketing and brand ...
Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3
... is the liquid elixir that nurtures the growth of billions ... ample supply of water for farming and agriculture often means ... world, however, suffer from the opposite - the growing scarcity ... drought and desertification to climate change and climate variability, pollution, ...
... DC Scientists at the Lombardi Comprehensive Cancer Center at ... million grant to tease apart in the most comprehensive ... in breast cells in cancer development and treatment. This protein ... breast cancer and how she will fare during her treatment. ...
... 22nd, 2010-Riparian areas, ecosystems caught between the land ... temporal variability. Effectively managing and protecting riparian areas ... concepts. Fortunately, scientists are investigating new approaches in ... One of those approaches is photography. By taking ...
Cached Biology News:More water for life 2More water for life 3Lombardi receives $7.5 million grant for Breast Cancer Center for Cancer Systems Biology 2Lombardi receives $7.5 million grant for Breast Cancer Center for Cancer Systems Biology 3Learning about riparian areas from photographs 2
Recognizes a full-length CLC-2 voltage-gated Cl- protein and not with other known proteins tested so far....
... 2, Monoclonal Antibody, Unconjugated Applications: ... dilution. ICC: Use at an assay dependent dilution. ... 10 ug/ml, this concentration is determined using a ... 40 kDa. Not tested in other applications. ...
Recognizes TWIK-2. Does not cross react with any other known proteins....
Anti human PPAR gamma2 mouse monoclonal antibody...
Biology Products: